RELMADA THERAPEUTICS, INC. Sales-type Lease, Selling Profit (Loss)
RELMADA THERAPEUTICS, INC. (RLMD) reported Sales-type Lease, Selling Profit (Loss) of $96.40 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesTypeLeaseSellingProfitLoss · last filed 2023-08-08
- RELMADA THERAPEUTICS, INC. sales-type lease, selling profit (loss) for the quarter ending 2023-06-30 was $0.00.
- RELMADA THERAPEUTICS, INC. sales-type lease, selling profit (loss) for the quarter ending 2023-03-31 was $96.40K.
| Period end | Sales-type Lease, Selling Profit (Loss) 3 month | Sales-type Lease, Selling Profit (Loss) 6 month |
|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $96.40K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $96.40K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |